Molecular mechanisms of inherited demyelinating neuropathies

GLIA

Volumn 56, Issue 14, 2008, Pages 1578-1589

  Scherer, Steven S ^a   Wrabetz, Lawrence ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Mutation; Myelin; Schwann cell; Signal transduction; Transcription.

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYELIN PROTEIN;

ANIMAL; DEMYELINATING DISEASE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; IMMUNOLOGY; METABOLISM; MYELIN SHEATH; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NERVE; POLYRADICULONEUROPATHY; REVIEW; SCHWANN CELL;

ANIMALS; DEMYELINATING DISEASES; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HEREDITARY MOTOR AND SENSORY NEUROPATHIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELIN PROTEINS; MYELIN SHEATH; PERIPHERAL NERVES; POLYRADICULONEUROPATHY; SCHWANN CELLS;

EID: 60149083988     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20751     Document Type: Article

References (168)

1. Abrams CK, Oh S, Ri Y, Bargiello TA. 2000. Mutations in connexin 32: The molecular and biophysical bases for the X-linked form of Charcot- Marie-Tooth disease. Brain Res Rev 32:203-214.
2. Adlkofer K, Frei R, Neuberg DH-H, Zielasek J, Toyka KV, Suter U. 1997a. Heterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating peripheral neuropathy. J Neurosci 17:4662-4671.
3. Adlkofer K, Naef R, Suter U. 1997b. Analysis of compound heterozygous mice reveals that the Trembler mutation can behave as a gainof- function allele. J Neurosci Res 49:671-680.
4. Aguayo AJ, Attiwell M, Trecarten J, Perkins CS, Bray CM. 1977. Abnormal myelination in transplanted Trembler mouse Schwann cells. Nature 265:73-75.
5. Ahn M, Lee J, Gustafsson A, Enriquez A, Lancaster E, Sul J-Y, Haydon PG, Paul DL, Huang Y, Abrams CK, Scherer SS. 2008. Cx29 and Cx32, two connexins expressed by myelinating glia, do not interact and are functionally distinct. J Neurosci Res 86:992-1006.
6. Altevogt BM, Kleopa KA, Postma FR, Scherer SS, Paul DL. 2002. Cx29 is uniquely distributed within myelinating glial cells of the central and peripheral nervous systems. J Neurosci 22:6458-6470.
7. Apfel SC. 2002. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, what does the future hold? Int Rev Neurobiol 50:393-413.
8. Azzedine H, Bolino A, Taieb T, Birouk N, Di Duca M, Bouhouche A, Benamou S, Mrabet A, Hammadouche T, Chkili T, Gouider R, Ravazzolo R, Brice A, Laporte J, Le Guern E. 2003. Mutations in MTMR13, a new pseudo-phosphatase homologue of MTMR2 and Sbf1, are responsible for an autosomal recessive demyelinating form of Charcot- Marie-Tooth disease associated with early-onset glaucoma. Amer J Hum Genet. 72: 1141-1153.
9. Balice-Gordon RJ, Bone LJ, Scherer SS. 1998. Functional gap junctions in the Schwann cell myelin sheath. J Cell Biol 142:1095-1104.
10. Beauvais K, Furby A, Latour P. 2006. Clinical, electrophysiological and molecular genetic studies in a family with X-linked dominant Charcot- Marie-Tooth neuropathy presenting a novel mutation in GJB1 promoter and a rare polymorphism in LITAF/SIMPLE. Neuromuscular Disord 16:14-18.
11. Bennett CL, Shirk AJ, Huynh HM, Street VA, Nelis E, VanMaldergem L, DeJonghe P, Jordanova A, Guergueltcheva V, Tournev I, Van den Bergh P, Seeman P, Mazanec R, Prochazka T, Kremensky I, Haberlova J, Weiss MD, Timmerman V, Bird TD, Chance PF. 2004. SIMPLE mutation in demyelinating neuropathy and distribution in sciatic nerve. Ann Neurol 55:713-720.
12. Benninger Y, Thurnherr T, Pereira JA, Krause S, Wu X, Chrostek- Grashoff A, Herzog D, Nave KA, Franklin RJM, Meijer D, Brakebusch C, Suter U, Relvas JB. 2007. Essential and distinct roles for cdc42 and rac1 in the regulation of Schwann cell biology during peripheral nervous system development. J Cell Biol 177:1051-1061.
13. Berciano J, Garcia A, Combarros O. 2003. Initial semeiology in children with Charcot-Marie-Tooth disease 1A duplication. Muscle Nerve 27:34-39.
14. Berger P, Berger I, Schaffitzel C, Tersar K, Volkmer B, Suter U. 2006. Multi-level regulation of myotubularin-related protein-2 phosphatase activity by myotubularin-related protein-13/set-binding factor-2. Hum Mol Genet 15:569-579.
15. Berger P, Bonneick S, Willi S, Wymann M, Suter U. 2002. Loss of phosphatase activity in myotubularin-related protein 2 is associated with Charcot-Marie-Tooth disease type 4B1. Hum Mol Genet 11:1569- 1579.
16. Berger P, Sirkowski EE, Scherer SS, Suter U. 2004. Expression analysis of the N-myc downstream-regulated gene 1 (NDRG1) indicates that myelinating Schwann cells are the primary disease target in Hereditary Motor and Sensory Neuropathy-Lom. Neurobiol Dis 17:290-299.
17. Bergoffen J, Scherer SS, Wang S, Oronzi-Scott M, Bone L, Paul DL, Chen K, Lensch MW, Chance P, Fischbeck K. 1993. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 262:2039- 2042.
18. Bolino A, Bolis A, Previtali SC, Dina G, Bussini S, Dati G, Amadio S, DelCarro U, Mruk DD, Feltri ML, Cheng CY, Quattrini A, Wrabetz L. 2004. Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis. J Cell Biol 167:711-721.
19. Bolino A, Muglia M, Conforti FL, LeGuern E, Salih MAM, Georgiou DM, Christodoulou K, Hausmanowa-Petrusewicz I, Mandich P, Schenone A, Gambardella A, Bono F, Quattrone A, Devoto M, Monaco AP. 2000. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet 25:17-19.
20. Bolis A, Coviello S, Bussini S, Dina G, Pardini C, Previtali SC, Malaguti M, Morana P, DelCarro U, Feltri ML, Quattrini A, Wrabetz L, Bolino A. 2005. Loss of Mtmr2 phosphatase in Schwann cells but not in motor neurons causes Charcot-Marie-Tooth type 4B1 neuropathy with myelin outfoldings. J Neurosci 25:8567-8577.
21. Bondurand N, Girard M, Pingault V, Lemort N, Dubourg O, Goossens M. 2001. Human connexin 32, a gap junction protein altered in the Xlinked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. Hum Mol Genet 10:2783-2795.
22. Bonneick S, Boentert M, Berger P, Atanasoski S, Mantei N, Wessig C, Toyka KV, Young P, Suter U. 2005. An animal model for Charcot- Marie-Tooth disease type 4B1. Hum Mol Genet 14:3685-3695.
23. Bostock H, Sears TA, Sherratt RM. 1981. The effects of 4-aminopyridine and tetrathylammonium ions on normal and demyelinated mammalian nerve fibers. J Physiol 313:301-315.
24. Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B, Swanson PD, Odelberg SJ, Disteche CM, Bird TD. 1993. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 72:143-151.
25. Chow CY, Zhang Y, Dowling JJ, Jin N, Adamska M, Shiga K, Szigeta K, Shy ME, Zhang X, Li J, Lupski JR, Weisman LS, Meisler MH. 2007. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 448:68-72.
26. Colby J, Nicholson R, Dickson KM, Orfali W, Naef R, Suter U, Snipes GJ. 2000. PMP22 carrying the trembler or trembler-J mutation is intracellularly retained in myelinating Schwann cells. Neurobiol Dis 7:561-573.
27. Court FA, Sherman DL, Pratt T, Garry EM, Ribchester RR, Cottrell DF, Fleetwood-Walker SM, Brophy PJ. 2004. Restricted growth of Schwann cells lacking Cajal bands slows conduction in myelinated nerves. Nature 431:191-195.
28. Decker L, Desmarquet-Trin-Dinh C, Taillebourg E, Ghislain J, Vallat JM, Charnay P. 2006. Peripheral myelin maintenance is a dynamic process requiring constant Krox20 expression. J Neurosci 26:9771- 9779.
29. Delague V, Jacquier A, Hamadouche T, Poitelon Y, Baudot C, Boccaccio I, Chouery E, Chaouch M, Kassouri N, Jabbour R, Grid D, Megarbane A, Haase G, Levy N. 2007. Mutations in FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal recessive Charcot-Marie-Tooth type 4H. Am J Hum Genet 81:1-16.
30. Denarier E, Forghani R, Farhadi HF, Dib S, Dionne N, Friedman HC, Lepage P, Hudson TJ, Drouin RG, Peterson A. 2005. Functional organization of a Schwann cell enhancer. J Neurosci 25:11210-11217.
31. Desmazieres A, Decker L, Vallat J-M, Charnay P, Gilardi-Hebenstreit P. 2008. Disruption of Krox20-Nab interaction in the mouse leads to peripheral neuropathy with biphasic evolution. J Neurosci 28:5891- 5900.
32. Di Muzio A, De Angelis MV, Di Fulvio P, Ratti A, Pizzuti A, Stuppia L, Gambi D, Uncini A. 2003. Dysmyelinating sensory-motor neuropathy in merosin-deficient congenital muscular dystrophy. Muscle Nerve 27:500-506.
33. Di Paolo G, De Camilli P. 2006. Phosphoinositides in cell regulation and membrane dynamics. Nature 443:651-657.
34. Dickson KM, Bergeron JJM, Shames I, Colby J, Nguyen DT, Chevet E, Thomas DY, Snipes GJ. 2002. Association of calnexin with mutant peripheral myelin protein-22 ex vivo: A basis for "gain-of-function" ER diseases. Proc Natl Acad Sci USA 99:9852-9857.
35. Dubourg O, Azzedine H, Verny C, Durosier G, Birouk N, Gouider R, Salih M, Bouhouche A, Thiam A, Grid D, Mayer M, Ruberg M, Tazir M, Brice A, Le Guern E. 2006. Autosomal-recessive forms of Charcot- Marie-Tooth diseae. Neuromolecular Med 8:75-85.
36. Dupree JL, Coetzee T, Blight A, Suzuki K, Popko B. 1998. Myelin galactolipids are essential for proper node of Ranvier formation in the CNS. J Neurosci 18:1642-1649.
37. Dyck PJ, Karnes JL, Lambert EH. 1989. Longitudinal study of neuropathic deficits and nerve conduction abnormalities in hereditary motor and sensory neuropathy type 1. Neurology 39:1302-1308.
38. Dyck PJ, Lais AC, Offord KP. 1974. The nature of myelinated nerve fiber degeneration in dominately inherited hypertrophic neuropathy. Mayo Clinic Proc 49:34-39.
39. Fabrizi GM, Cavallaro T, Angiari C, Bertolasi L, Cabrini I, Ferrarini M, Rizzuto N. 2004. Giant axon and neurofilament accumulation in Charcot-Marie-Tooth disease type 2E. Neurology 62:1429-1431.
40. Fabrizi GM, Cavallaro T, Angiari C, Cabrini I, Taioli F, Malerba G, Bertolasi L, Rizzuto N. 2007. Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton. Brain 130:394-403.
41. Fabrizi GM, Simonati A, Morbin M, Cavallaro T, Taioli F, Benedetti MD, Edomi P, Rizzuto N. 1998. Clinical and pathological correlations in Charcot-Marie-Tooth neuropathy type 1A with the 17p11.2p12 duplication: A cross-sectional morphometric and immunohistochemical study in twenty cases. Muscle Nerve 21:869-877.
42. Feltri M-L, Suter U, Relvas JB. 2008. The function of Rho GTPases in ensheathment and myelination. Glia 56:1508-1517.
43. Feltri ML, Wrabetz L. 2005. Laminins and their receptors in Schwann cells and hereditary neuropathies. J Peripher Nerv Syst 10: 128-143.
44. Fortun J, Li J, Go J, Fenstermaker A, Fletcher BS, Notterpek L. 2005. Impaired proteasome activity and accumulation of ubiquitinated substrates in a hereditary neuropathy model. J Neurochem 92:1531- 1541.
45. Fortun J, Verrier JD, Go JC, Madorsky I, Dunn WA, Notterpek L. 2007. The formation of peripheral myelin protein 22 aggregates is hindered by the enhancement of autophagy and expression of cytoplasmic chaperones. Neurobiol Dis 25:1531-1541.
46. Frei R, Motzing S, Kinkelin I, Schachner M, Koltzenburg M, Martini R. 1999. Loss of distal axons and sensory Merkel cells and features indicative of muscle denervation in hindlimbs of P0-deficient mice. J Neurosci 19:6058-6067.
47. Gabrëels-Festen AAWM, Joosten EMG, Gabreels FJM, Jennekens FGI, Kempen TWJ. 1992. Early morphological features in dominantly inherited demyelinating motor and sensory neuropathy (HMSN Type- I). J Neurol Sci 107:145-154.
48. Garcia CA, Malamut RE, Englnad JD, Parry GS, Liu P, Lupski JR. 1995. Clinical variability in two pairs of identical twins with the Charcot-Marie-Tooth disease type 1A duplication. Neurology 45:2090-2093.
49. Giese KP, Martini R, Lemke G, Soriano P, Schachner M. 1992. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 71:565-576.
50. Grandis M, Vigo T, Passalacqua M, Jian M, Scazzola S, La Padula V, Brucal M, Benvenuto F, Nobbio L, Cadoni A, Mancardi GL, Kamholz J, Shy ME, Schenone A. 2008. Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. Hum Mol Genet 17:1877-1889.
51. Hanemann CO, D'Urso D, Gabrëels-Festen AAWM, M̈uller HW. 2000. Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot-Marie-Tooth type 1A. Brain 123:1001-1006.
52. Harding AE, Thomas PK. 1980. The clinical features of hereditary motor and sensory neuropathy types I, II. Brain 103:259-280.
53. Hayasaka K, Ohnishi A, Takada G, Fukushima Y, Murai Y. 1993. Mutation of the myelin P0 gene in Charcot-Marie-Tooth neuropathy type-1. Biochem Biophys Res Commun 194:1317-1322.
54. Houlden H, Girard M, Cockerell C, Ingram D, Wood NW, Goossens M, Walker RWH, Reilly MM. 2004. Connexin 32 promoter P2 mutations: A mechanism of peripheral nerve dysfunction. Ann Neurol 56:730-734.
55. Houlden H, King RHM, Wood NW, Thomas PK, Reilly MM. 2001. Mutations in the 50 region of the myotubularin-related protein 2 (MTMR2) gene in autosomal recessive hereditary neuropathy with focally folded myelin. Brain 124:907-915.
56. Huang Y, Sirkowski EE, Stickney JT, Scherer SS. 2005. Prenylation-defective human connexin32 mutants are normally localized and function equivalently to wild-type connexin32 in myelinating Schwann cells. J Neurosci 25:7111-7120.
57. Huxley C, Passage E, Manson A, Putzu G, Figarella-Branger D, Pellissier JF, Fontes M. 1996. Construction of a mouse model of Charcot- Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 5:563-569.
58. Huxley C, Passage E, Robertson AM, Youl B, Huston S, Manson A, Saberan-Djoniedi D, Figarella-Branger D, Pellissier JF, Thomas PK, Fontes M. 1998. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet 7:449-458.
59. Inoue K, Khajavi M, Ohyama T, Hirabayashi S, Wilson J, Reggin JD, Mancias P, Butler IJ, Wilkinson MF, Wegner M, Lupski JR. 2004. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet 36:361-369.
60. Inoue K, Shilo K, Boerkoel CF, Crowe C, Sawady J, Lupski JR, Agamanolis DP. 2002. Congenital hypomyelinating neuropathy, central dysmyelination, and Waardenburg-Hirschsprung disease: Phenotypes linked by SOX10 mutation. Ann Neurol 52:836-842.
61. Inoue K, Tanabe Y, Lupski JR. 1999. Myelin deficiencies in both the central and the peripheral nervous systems associated with a SOX10 mutation. Ann Neurol 46:313-318.
62. Jang SW, LeBlanc SE, Roopra A, Wrabetz L, Svaren J. 2006. In vivo detection of Egr2 binding to target genes during peripheral nerve myelination. J Neurochem 98:1678-1687.
63. Jones EA, Jang SW, Mager GM, Chang L-W, Srinivasan R, Gokey NG, Ward RM, Nagarajan R, Svaren J. Interactions of Sox10 and Egr2 in myelin gene regulation. Neuron Glia Biol 3:377-387.
64. Kalaydjieva L, Gresham D, Gooding R, Heather L, Baas F, de Jonge R, Blechschmidt K, Angelicheva D, Chandler D, Worsley P, Rosenthal A,King RHM, Thomas PK. 2000. N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Amer J Hum Genet 67: 47-58.
65. Khajavi M, Inoue K, Wiszniewski W, Ohyama T, Snipes GJ, Lupski JR. 2005. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathycausing myelin protein zero-truncating mutants. Amer J Hum Genet 77:841-850.
66. Khajavi M, Shiga K, Wiszniewski W, He F, Shaw CA, Yan J, Wensel TG, Snipes GJ, Lupski JR. 2007. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: A potential therapy for inherited neuropathy. Amer J Hum Genet 81:438-453.
67. Kirschner DA,Wrabetz L, Feltri ML. 2004. The P0 gene. In: Lazzarini RA, editor. Myelin biology and disorders. New York: Elsevier. pp 523-545.
68. Koval M. 2006. Pathways and control of connexin oligomerization. Trends Cell Biol 16:159-166.
69. Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J, Kamholz J, Shy ME. 2000. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease. Brain 123:1516-1527.
70. Le N, Nagarajan R, Wang JYT, Araki T, Schmidt RE, Milbrandt J. 2005a. Analysis of congenital hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. Proc Nat Acad Sci USA 102:2596-2601.
71. Le N, Nagarajan R, Wang JYT, Svaren J, LaPash C, Araki T, Schmidt RE, Milbrandt J. 2005b. Nab proteins are essential for peripheral nervous system myelination. Nat Neurosci 8:932-940.
72. LeBlanc SE, Jang SW, Ward RM, Wrabetz L, Svaren J. 2006. Direct regulation of myelin protein zero expression by the Egr2 transactivator. J Biol Chem 281:5453-5460.
73. LeBlanc SE, Srinivasan R, Ferri C, Mager GM, GillianDaniel AL, Wrabetz L, Svaren J. 2005. Regulation of cholesterol/lipid biosynthetic genes by Egr2/Krox20 during peripheral nerve myelination. J Neurochem 93:737-748.
74. LeBlanc SE, Ward RM, Svaren J. 2007. Neuropathy-associated Egr2 mutants disrupt cooperative activation of protein zero by Egr2 and Sox10. Mol Cell Biol 27:3521-3529.
75. Lecar H, Ehrenstein G, Stillman I. 1971. Detection of molecular motion in lyophilized myelin by nuclear magnetic resonance. Biophys J 11:140-145.
76. Lupski JR, Garcia CA. 2001. Charcot-Marie-Tooth peripheral neuropathies and related disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill. pp 5759-5788.
77. Mager GM, Ward RM, Srinivasan R, Jang SW, Wrabetz L, Svaren J. Active gene repression by the EGR2/NAB complex during peripheral nerve myelination. J Biol Chem 283:18187-18197.
78. Magyar JP, Martini R, Ruelicke T, Aguzzi A, Adlkofer K, Dembic Z, Zielasek J, Toyka KV, Suter U. 1996. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci. 16: 5351-5360.
79. Martini R. 1997. Animal models for inherited peripheral neuropathies. J Anat 191:321-336.
80. Martini R. 2001. The effect of myelinating Schwann cells on axons. Muscle Nerve 24:456-466.
81. Matsuyama W, Nakagawa M, Takashima H, Osame M. 2002. Altered trafficking and adhesion function of MPZ mutations and phenotypes of Charcot-Marie-Tooth disease 1B. Acta Neuropathol 103:501-508.
82. Meyer zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW. 2007. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 61:61-72.
83. Murphy P, Topilko P, Schneider-Maunoury S, Seitanidou T, Baron-Van Evercooren A, Charnay P. 1996. The regulation of Krox-20 expression reveals important steps in the control of peripheral glial cell development. Development 122:2847-2857.
84. Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J. 2001. EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron 30:355-368.
85. Nave KA, Sereda MW, Ehrenreich H. 2007. Mechanisms of disease: Inherited demyelinating neuropathies - From basic to clinical research. Nat Clin Pract Neurol 3:453-464.
86. Nicholson G, Myers S. 2006. Intermediate forms of Charcot-Marie- Tooth neuropathy. Neuromolecular Med 8:123-130.
87. Niemann A, Berger P, Suter U. 2006. Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease. Neuromolecular Med 8:217- 242.
88. Occhi S, Zambroni D, Carro UD, Amadio S, Sirkowsi EE, Scherer SS, Campbell K, Moore SA, Chen Z-L, Strickland S, Di Muzio A, Uncini A, Wrabetz L, Feltri M-L. 2005. Both laminin and Schwann cell dystroglycan are nccessary for proper clustering of sodium channels at nodes of Ranvier. J Neurosci 25:9418-9427.
89. Ohnishi A, Mitsudome A, Murai Y. 1987. Primary segmental demyelination in the sural nerve in Cockayne's syndrome. Muscle Nerve 10:163-167.
90. Okuda T, Higashi Y, Kokame K, Tanaka C, Kondoh H, Miyata T. 2004. Ndrg1-deficient mice exhibit a progressive demyelinating disorder of peripheral nerves. Mol Cell Biol 24:3949-3956.
91. Ouvrier R, Geevasingha N, Ryan MM. 2007. Autosomal-recessive and X-linked forms of hereditary motor and sensory neuropathy in childhood. Muscle Nerve 36:131-143.
92. Ouvrier RA, McLeod JG, Pollard JD. 1999. Peripheral neuropathy in childhood, London: MacKeith Press. 335 p.
93. Pareek S, Suter U, Snipes GJ, Welcher AA, Shooter EM, Murphy RA. 1993. Detection and processing of peripheral myelin protein PMP22 in cultured Schwann cells. J Biol Chem 2.68: 10372-10379.
94. Pareyson D, Schenone A, Fabrizi GM, Santoro L, Padua L, Quattrone A, Vita G, Gemignani F, Visioli F, Solari A. 2006. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMTTRIAAL): The study protocol [EudraCT no.: 2006-000032-27]. Pharmacol Res 54:436-441.
95. Parkinson DB, Bhaskaran A, Arthur-Farraj P, Noon LA, Woodoo A, Lloyd AC, Feltri ML, Wrabetz L, Behrens A, Mirsky R, Jessen KR. 2008. c-Jun is a negative regulator of myelination. J Cell Biol 181:625-637.
96. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M. 2004. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot- Marie-Tooth disease. Nature Med 10:396-401.
97. Patel PI, Roa BB, Welcher AA, Schoenerscott R, Trask BJ, Pentao L, Snipes GJ, Garcia CA, Francke U, Shooter EM, Lupski JR, Suter U. 1992. The gene for the peripheral myelin protein-PMP-22 is a candidate for Charcot-Marie-Tooth disease type-1A. Nat Genet 1:159-165.
98. Pennuto M, Tinelli E, Malaguti MC, Del Carro U, D'Antonio M, Ron D, Quattrini A, Feltri M-L, Wrabetz L. 2008. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. Neuron 57:393-405.
99. Pingault V, Bondurand N, LeCaignec C, Tardieu S, Lemort N, Dubourg O, Le Guern E, Goossens M, Boespflug-Tanguy O. 2001. The SOX10 transcription factor: Evaluation as a candidate gene for central and peripheral hereditary myelin disorders. J Neurol 248:496-499.
100. Pingault V, Guiochon-Mantel A, Bondurand N, Faure C, Lacroix C, Lyonnet S, Goosens M, Landrieu P. 2000. Peripheral neuropathy with hypomyelination, chronic intestinal pseudo-obstruction and deafness: A developmental "neural crest syndrome" related to a SOX10 mutation. Ann Neurol 48:671-676.
101. Previtali S, Zerega B, Sherman D, Brophy P, Dina G, King R, Salih M, Feltri M, Quattrini A, Ravazzolo R, Wrabetz L, Monaco A, Bolino A. 2003. Myotubularin-related 2 protein phosphatase and neurofilament light chain protein, both mutated in CMT neuropathies, interact in peripheral nerve. Hum Mol Genet 12:1713-1723.
102. Previtali SC, Quattrini A, Bolino A. 2007. Charcot-Marie-Tooth type 4B demyelinating neuropathy: Deciphering the role of MTMR phosphatases. Expert Rev Mol Med 9:1-16.
103. Robaglia-Schlupp A, Pizant J, Norreel JC, Passage E, Saberan-Djoneidi D, Ansaldi JL, Vinay L, Figarella-Branger D, Levy N, Clarac F, Cau P, Pellissier JF, Fontes M. 2002. PMP22 overexpression causes dysmyelination in mice. Brain 125:2213-2221.
104. Robertson AM, Perea J, McGuigan A, King RHM, Muddle JR, Gabrëels-Festen AA, Thomas PK, Huxley C. 2002. Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J Anat 200:377-390.
105. Robinson FL, Dixon JE. 2005. The phosphoinositide-3-phosphatase MTMR2 associates with MTMR13, a membrane-associated pseudophosphatase also mutated in type 4B Charcot-Marie-Tooth disease. J Biol Chem 280:31699-31707.
106. Robinson FL, Niesman IR, Beiswenger KK, Dixon JE. 2008. Loss of the inactive myotubularin-related phosphatase Mtmr13 leads to a Charcot- Marie-Tooth 4B2-like peripheral neuropathy in mice. Proc Nat Acad Sci USA 105:4916-4921.
107. Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, Mendell JR. 2005. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 65:681-689.
108. Saher G, Brugger B, Lappe-Siefke C, Mobius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA. 2005. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 8:468-475.
109. Saifi GM, Szigeti K, Wiszniewski W, Shy ME, Krajewski K, Hausmanowa- Petrusewicz I, Kochanski A, Reeser S, Mancias P, Butler I, Lupski JR. 2005. SIMPLE mutations in Charcot-Marie-Tooth disease and the potential role of its protein product in protein degradation. Hum Mutat 25:372-383.
110. Saito F, Moore SA, Barresi R, Henry MD, Messing A, RossBarta SE, Cohn RD, Williamson RA, Sluka KA, Sherman DL, Low PA, Wrabetz L, Feltri M-L, Campbell KP. 2003. Unique role of dystroglycan in peripheral nerve myelination, nodal structure, and sodium channel stabilization. Neuron 38:747-758.
111. Salzer JL, Brophy PJ, Peles E. 2008. Molecular domains of myelinated axons. Glia 56:1532-1540.
112. Samsam M, Mi WQ, Wessig C, Zielasek R, Toyka KV, Coleman MP, Martini R. 2003. The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. J Neurosci 23:2833-2839.
113. Sancho S, Magyar JP, Aguzzi A, Suter U. 1999. Distal axonopathy in peripheral nerves of PMP22 mutant mice. Brain 122:1563-1577.
114. Sargiannidou I, Ahn M, Enriquez AD, Peinado A, Reynolds R, Abrams C, Scherer SS, Kleopa KA. 2008. Human oligodendrocytes express Cx31.3: Function and interactions with Cx32 mutants. Neurobiol Dis 30:221-233.
115. Scherer SS, Salzer J. 2001. Axon-Schwann cell interactions in peripheral nerve degeneration and regeneration. In: Jessen KR, Richardson WD, editors. Glial cell development. Oxford: Oxford University Press. pp 299-330.
116. Scherer SS, Xu Y-T, Nelles E, Fischbeck K, Willecke K, Bone LJ. 1998. Connexin32-null mice develop a demyelinating peripheral neuropathy. Glia 24:8-20.
117. Schmitt FO, Bear RS, Clark GL. 1935. X-ray diffraction studies on nerve. Radiology 25:131-151.
118. Schreiner S, Cossais F, Fischer K, Scholz S, Bosl MR, Holtmann B, Sendtner M, Wegner M. 2007. Hypomorphic Sox10 alleles reveal novel protein functions and unravel developmental differences in glial lineages. Development 134:3271-3281.
119. Senderek J, Bergmann C, Stendel C, Kirfel J, Verpoorten N, De Jonghe P, Timmerman V, Chrast R, Verheijen MHG, Lemke G, Battaloglu E, Parman Y, Erdem S, Tan E, Topaloglu H, Hahn A, Muller-Felber W, Rizzuto N, Fabrizi GM, Stuhrmann M, Rudnik-Schoneborn S, Zuchner S, Schroder JM, Buchheim E, Straub V, Klepper JR, Huehne K, Rautenstrauss B, Buttner R, Nelis E, Zerres K. 2003a. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet 73:1106-1119.
120. Senderek J, Bergmann C, Weber S, Ketelsen UP, Schorle H, Rudnik- Schoneborn S, Buttner R, Buchheim E, Zerres K. 2003b. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet 12:349-356.
121. Sereda M, Griffiths I, Puhlhofer A, Stewart H, Rossner MJ, Zimmermann F, Magyar JP, Schneider A, Hund E, Meinck HM, Suter U, Nave KA. 1996. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16:1049-1060.
122. Sereda MW, Horste GMZ, Suter U, Uzma N, Nave KA. 2003. Therapeutic administration of progesterone antagonist in a model of Charcot- Marie-Tooth disease (CMT-1A). Nature Med 9:1533-1537.
123. Sghirlanzoni A, Pareyson D, Balestrini MR, Bellone E, Berta E, Ciano C, Mandich P, Marazzi R. 1992. HMNS III phenotype due to homozygous expression of a dominant HMNS II gene. Neurology 42:2201- 2203.
124. Shames I, Fraser A, Colby J, Orfali W, Snipes GJ. 2003. Phenotypic differences between peripheral myelin protein-22 and myelin protein zero (P0) mutations assocated with Charcot-Marie-Tooth-related diseases. J Neuropathol Exp Neurol 62:751-764.
125. Shapiro L, Doyle JP, Hensley P, Colman DR, Hendrickson WA. 1996. Crystal stucture of the extracellular domain from P0, the major structural protein of peripheral nerve myelin. Neuron 17:435-449.
126. Sherman D, Brophy P. 2004. The periaxin gene. In: Lazzarini RA, editor. Myelin biology and disorders. San Diego: Elsevier Academic Press. pp 633-642.
127. Shy ME. 2006. Therapeutic strategies for the inherited neuropathies. Neuromolecular Med 8:255-278.
128. Shy ME, Arroyo E, Sladky J, Menichella D, Jiang H, Kamholz J, Scherer SS. 1997. Heterozygous P0 knockout mice develop a peripheral neuropathy that resembles chronic inflammatory demyelinating polyneuropathy (CIDP). J Neuropathol Exp Neurol 56:811-821.
129. Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, Li J, Lewis RA, Reilly M. 2005a. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64:1209-1214.
130. Shy ME, Jani A, Krajewski K, Grandis M, Lewis RA, Li J, Shy RR, Balsamo J, Lilien J, Garbern JY, Kamholz J. 2004. Phenotypic clustering in MPZ mutations. Brain 127:371-384.
131. Shy ME, Lupski JR, Chance PF, Klein CJ, Dyck PJ. 2005b. Hereditary motor and sensory neuropathies: An overview of clinical, genetic, electrophysiologic, and pathologic features. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy. Philadelphia: Saunders. pp 1623- 1658.
132. Shy ME, Siskind C, Swan ER, Krajewski KM, Doherty T, Fuerst DR, Ainsworth PJ, Lewis RA, Scherer SS, Hahn A. 2007. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 68:849-855.
133. Shyu A-B, Wilkinson MF, van Hoof A. 2008. Messenger RNA regulation: To translate or to degrade. EMBO J 27:471-481.
134. Smith K, McDonald I, Miller D, Lassmann H. 2005. The pathophysiology of multiple sclerosis. In: Compston A, editor. McAlpine's multiple sclerosis. Oxford: Churchill Livingstone. pp 601-660.
135. Smits MG, Gabreels FJ, Renier WO, Joosten EM, Gabreels-Festen AA, ter Laak HJ, Pinckers AJ, Hombergen GC, Notermans SL, Thijssen HO. 1982. Peripheral and central myelinopathy in Cockayne's syndrome. Report of 3 siblings. Neuropediatrics 13:161-167.
136. Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C. 2003. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev CD001330.
137. Stendel C, Roos A, Deconinck T, Pereira J, Castagner F, Niemann A, Kirschner J, Korinthenberg R, Ketelsen UP, Battaloglu E, Parman Y, Nicholson G, Ouvrier R, Seeger J, De Jonghe P, Weis J, Kruttgen A, Rudnik-Schoneborn S, Bergmann C, Suter U, Zerres K, Timmerman V, Relvas JB, Senderek J. 2007. Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4. Am J Hum Genet .81: 158-164.
138. Street VA, Bennett CL, Goldy JD, Shirk AJ, Kleopa KA, Tempel BL, Lipe HP, Scherer SS, Bird TD, Chance PF. 2003. Mutations of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie- Tooth disease 1C. Neurology 60:22-26.
139. Suter U. 2004. PMP22 gene. In: Lazzarini RA, editor. Myelin biology and disorders. San Diego: Elsevier Academic Press. pp 547-564.
140. Suter U. 2007. Phosphoinositides and Charcot-Marie-tooth disease: New keys to old questions. Cell Mol Life Sci 64:3261-3265.
141. Suter U, Scherer SS. 2003. Disease mechanisms in inherited neuropathies. Nat Rev Neurosci 4:714-726.
142. Svaren J, Meijer D. 2008. The molecular machinery of myelin gene transcription. Glia 56:1541-1551.
143. Svaren J, Sevetson BR, Apel E, Zimonjic DB, Popescu NC, Milbrandt J. 1996. NAB2, a corepressor of NGFI-A (Erg-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol 16:3545- 3553.
144. Tang X, Metzger D, Amar S. 2006. LPS-induced TNF-a factor (LITAF)- deficient mice epxress reduced LPS-induced cytokine evidence for LITAF-dependent LPS signaling pathways. Proc Nat Acad Sci USA 103:13777-13782.
145. Tersar K, Boentert M, Berger P, Bonneick S, Wessig C, Toyka KV, Young P, Suter U. 2007. Mtmr13/Sbf2-deficient mice: An animal model for CMT4B2. Hum Mol Genet 16:2991-3001.
146. Thomas PK, Marques W, Davis MB, Sweeney MG, King RHM, Bradley JL, Muddle JR, Tyson J, Malcolm S, Harding AE. 1997. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 120:465-478.
147. Tobler AR, Liu N, Mueller L, Shooter EM. 2002. Differential aggregation of the Trembler and TremblerJ mutants of peripheral myelin protein 22. Proc Natl Acad Sci USA 99:483-488.
148. Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Ben Younes Chennoufi A, Seitanidou T, Babinet C, Charnay P. 1994. Krox-20 controls myelination in the peripheral nervous system. Nature 371:796-799.
149. Trapp BD, Kidd GJ. 2004. Structure of the myelinated axon. In: Lazzarini RA, editor. Myelin biology and disorders. San Diego: Elsevier. pp 3-27.
150. Vallat JM, Sindou P, Preux PM, Tabaraud F, Milor AM, Couratier P, Le Guern E, Brice A. 1996. Ultrastructural PMP22 expression in inherited demyelinating neuropathies. Ann Neurol 39:813-817.
151. Vallat JM, Tazir M, Magelaine C, Sturtz F, Grid D. 2005. Autosomal-recessive Charcot-Marie-Tooth diseases. J Neuropathol Exp Neurol 64:363-370.
152. van der Pluijm I, Garinis GA, Brandt RM, Gorgels TG, Wijnhoven SW, Diderich KE, de Wit J, Mitchell JR, van Oostrom C, Beems R, Niedernhofer LJ, Velasco S, Friedberg EC, Tanaka K, van Steeg H, Hoeijmakers JH, van der Horst GT. 2007. Impaired genome maintenance suppresses the growth hormone-insulin-like growth factor 1 axis in mice with Cockayne syndrome. PLoS Biol 5:e2.
153. VanSlyke JK, Deschenes SM, Musil LS. 2000. Intracellular transport, assembly, and degradation of wild-type and disease-linked mutant gap junction proteins. Mol Biol Cell 11:1933-1946.
154. Verheij JB, Sival DA, van der Hoeven JH, Vos YJ, Meiners LC, Brouwer OF, van Essen AJ. 2006. Shah-Waardenburg syndrome and PCWH associated with SOX10 mutations: A case report and review of the literature. Eur J Paediatr Neurol 10:11-17.
155. Verhoeven K, De Jonghe P, VandePutte T, Nelis E, Zwijsen A, Verpoorten N, DeVriendt E, Jacobs A, Van Gerwen V, Francis A, Ceuterick C, Huylebroeck D, Timmerman V. 2003. Slowed conduction and thin myelination of peripheral nerves associated with mutant Rho guanine-nucleotide exchange factor 10. Am J Hum Genet 73:926-932.
156. Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, Lupski JR. 1998. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 18: 382-384.
157. Warner LE, Svaren J, Milbrandt J, Lupski JR. 1999. Functional consequences of mutations in the early growth response 2 gene (EGR2) correlate with severity of human myelinopathies. Hum Mol Genet 8:1245-1251.
158. Waxman SG, Kocsis JD, Black JA. 1995. Pathophysiology of demyelinated axons. In: Waxman SG, Kocsis JD, Stys PK, editors. The axon. Oxford: Oxford University Press. pp 638-461.
159. Welch E, Barton E, Zhuo J, Tomizawa Y, Friesen W, Trifillis P, Paushkin S, Patel M, Trotta C, Hwang S, Wilde R, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon Y, Corson D, Turpoff A, Campbell J, Conn M, Khan A, Almstead N, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom A, Colacino J, Babiak J, Ju W, Hirawat S, Northcutt V, Miller L, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz S, Sweeney H. 2007. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:42-43.
160. Wrabetz L, DAntonio M, Pennuto M, Dati G, Tinelli E, Fratta P, Previtali S, Imperiale D, Zielasek J, Toyka K, Avila RL, Kirschner DA, Messing A, Feltri ML, Quattrini A. 2006. Different intracellular pathomechanisms produce diverse Myelin Protein Zero neuropathies in transgenic mice. J Neurosci 26:2358-2368.
161. Wrabetz L, Feltri ML, Kleopa KA, Scherer SS. 2004a. Inherited neuropathies: Clinical, genetic, and biological features. In: Lazzarini RA, editor. Myelin biology and disorders. San Diego: Elsevier Academic Press. pp 905-951.
162. Wrabetz L, Feltri ML, Suter U. 2004b. Models of Charcot-Marie-Tooth disease. In: Lazzarini RA, editor. Myelin biology and disorders. San Diego: Elsevier Academic Press. pp 1143-1168.
163. YumSW, Kleopa KA, Shumas S, Scherer SS. 2002.Diverse trafficking abnormalities for connexin32 mutants causingCMTX.NeurobiolDis 11:43-52.
164. Zhang K, Filbin MT. 1998. Myelin P0 protein mutated at Cys21 has a dominant- negative effect on adhesion of wild type P0. JNeurosci Res 53:1-6.
165. Zhang X, Chow C, Sahenk Z, Shy ME, Meisler MH, Li J. Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration. Brain (in press).
166. Zhang Y, Zolov SN, Chow CY, Slutsky SG, Richardson SC, Piper RC, Yang B, Nau JJ, Westrick RJ, Morrison SJ, Meisler MH, Weisman LS. 2007. Loss of Vac14, a regulator of the signaling lipid phosphatidylinositol 3,5-bisphosphate, results in neurodegeneration in mice. Proc Nat Acad Sci USA 104:17518-17523.
167. Zielasek J, Martini R, Toyka KV. 1996. Functional abnormalities in P0- deficient mice resemble human hereditary neuropathies linked to P0 gene mutations. Muscle Nerve 19:946-952.
168. Zorick TS, Syroid DE, Arroyo E, Scherer SS, Lemke G. 1996. The transcription factors SCIP and Krox-20 mark distinct stages and cell fates in Schwann cell differentiation. Mol Cell Neurosci 8:129-145.